Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
The study suggests that even small changes in lifestyle habits can have a significant impact on life expectancy, highlighting the importance of physicians’ role in supporting patients in making these changes.
All Specialties August 7th 2023
Semaglutide, a familiar medication for obesity and type 2 diabetes, might pave a new path in managing alcohol dependence. Unearth the potential of this medication, which could reshape our understanding of alcohol dependence treatment.
Endocrinology, Diabetes, Metabolism June 21st 2023
Combining alcohol and caffeine is more likely to cause drinkers to underestimate their level of intoxication. The practice among young people leads to more reports of unprotected or unwanted sex, DUI, riding with intoxicated drives, and alcohol-related injury. The combination can also increase blood pressure, raising the risk of stroke and heart attack in at-risk populations.
All Specialties May 9th 2023
ACP Internist
Excessive alcohol use has continued to climb since the beginning of the COVD pandemic, and is a causal factor in one of every five deaths in the 20-to-49-year age group in the US.
Psychiatry March 14th 2023
Addiction Professional
Oregon Health & Science University (OHSU) researchers were searching a genetic database for compounds that could suppress the expression of genes previously linked to heavy alcohol use. They put apremilast to the test in two animal models with a genetic risk of binge drinking, as well as in mice from other labs. In each case, apremilast reduced alcohol consumption by increasing activity in the nucleus accumbens, the brain region involved in controlling alcohol intake. Scripps Research Institute then assessed 51 patients over 11 days of treatment and discovered that trial participants’ alcohol consumption was reduced from an average of five drinks per day to two.
Neurology March 7th 2023
The Journal of Clinical Investigation (JCI)
PDE4 is linked to alcohol and nicotine addiction, so the researchers prioritized apremilast, a newer PDE4 inhibitor for psoriasis, as ideal for repurposing and tested it in multiple animal strains and models, as well as a human Phase IIa study. In mouse models of genetic risk for drinking to intoxication, they discovered that apremilast reduced binge-like alcohol intake and behavioral measures of alcohol motivation.
Family Medicine/General Practice March 6th 2023